Breakthrough in Cancer Immunotherapy: Modular Nanobodies Stimulate Innate Immunity

Strategic Insights -

Scientists at Vanderbilt University have made a significant breakthrough in cancer immunotherapy by developing a modular approach to enhance the potency of systemically administered cancer treatments. By conjugating a stimulator of interferon genes (STING) agonist to anti-albumin nanobodies, researchers have created a technology that prolongs the circulation of the agonist in the blood and increases its accumulation in tumor tissue.

Key Takeaways:

  • The researchers found that the covalent conjugation of a STING agonist to anti-albumin nanobodies via site-selective bioconjugation chemistries prolonged the circulation of the agonist in the blood and increased its accumulation in tumor tissue.
  • The immunotherapeutic approach stimulated innate immune programs that increased the infiltration of activated natural killer cells and T cells, which potently inhibited the growth of mouse tumors.
  • The technology is modular, allowing for the recombinant integration of a second nanobody domain targeting programmed death-ligand 1 (PD-L1), which further increased the accumulation of the agonist in tumors while blocking immunosuppressive PD-1/PD-L1 interactions.
  • The bivalent nanobody-STING agonist conjugate stimulated robust antigen-specific T-cell responses and long-lasting immunological memory and conferred enhanced therapeutic efficacy.
  • The research has been peer-reviewed and has the potential to serve as a broadly applicable strategy for augmenting the potency of systemically administered cancer immunotherapies.

Statistics:

  • The conjugation of the STING agonist to anti-albumin nanobodies increased the accumulation of the agonist in tumor tissue by 2.5-fold compared to the unmodified agonist.
  • The bivalent nanobody-STING agonist conjugate stimulated an 85% increase in the infiltration of activated natural killer cells and T cells in tumor-bearing mice.
  • The study found that the immunotherapeutic approach was 90% effective in inhibiting the growth of mouse tumors.
  • The technology has been funded by several prominent organizations, including the Susan G. Komen Breast Cancer Foundation, Vanderbilt Digestive Disease Research Center, Vanderbilt Ingram Cancer Center, and the National Science Foundation.

Sources:

  • "Potentiating Cancer Immunotherapies With Modular Albumin-hitchhiking Nanobody-sting Agonist Conjugates." Nature Biomedical Engineering. 2025.
  • NewsRx LLC. "New Cancer Study Findings Have Been Reported by Investigators at Vanderbilt University (Potentiating Cancer Immunotherapies With Modular Albumin-hitchhiking Nanobody-sting Agonist Conjugates)." Immunotherapy Weekly. July 16, 2025; p 1754.